Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

ardelyx inc - ARDX

ARDX

Close Chg Chg %
5.78 0.02 0.35%

Pre-Market

5.80

+0.02 (0.35%)

Volume: 2.95M

Last Updated:

Dec 30, 2025, 4:00 PM EDT

Trade Now

Company Overview: ardelyx inc - ARDX

ARDX Key Data

Open

$5.82

 Day Range

5.72 - 5.99

52 Week Range

3.21 - 6.78

 Market Cap

$1.40B

Shares Outstanding

242.97M

 Public Float

233.92M

Beta

0.55

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.24

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.77M

  

ARDX Performance

1 Week
 
 1.05%
 
1 Month
 
 0.00%
 
3 Months
 
 10.27%
 
1 Year
 
 14.40%
 
5 Years
 
 -10.36%
 

ARDX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 11
Full Ratings ➔

About ardelyx inc - ARDX

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

ARDX At a Glance

Ardelyx, Inc.
400 Fifth Avenue
Waltham, Massachusetts 02451
Phone 1-510-745-1700 Revenue 333.62M
Industry Pharmaceuticals: Major Net Income -39,136,000.00
Sector Health Technology 2024 Sales Growth 168.059%
Fiscal Year-end 12 / 2025 Employees 395
View SEC Filings

ARDX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 3.575
Price to Book Ratio 6.964
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -42.337
Enterprise Value to Sales 3.285
Total Debt to Enterprise Value 0.14

ARDX Efficiency

Revenue/Employee 844,594.937
Income Per Employee -99,078.481
Receivables Turnover 5.781
Total Asset Turnover 0.91

ARDX Liquidity

Current Ratio 4.58
Quick Ratio 4.308
Cash Ratio 3.213

ARDX Profitability

Gross Margin 84.228
Operating Margin -8.378
Pretax Margin -11.651
Net Margin -11.731
Return on Assets -10.673
Return on Equity -23.014
Return on Total Capital -11.978
Return on Invested Capital -14.401

ARDX Capital Structure

Total Debt to Total Equity 88.545
Total Debt to Total Capital 46.962
Total Debt to Total Assets 35.212
Long-Term Debt to Equity 87.643
Long-Term Debt to Total Capital 46.484
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Ardelyx Inc - ARDX

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
10.10M 52.16M 124.46M 333.62M
Sales Growth
+33.36% +416.57% +138.61% +168.06%
Cost of Goods Sold (COGS) incl D&A
5.53M 8.72M 19.09M 52.62M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.53M 4.60M 1.29M 2.06M
Depreciation
4.53M 4.60M 1.29M 2.06M
Amortization of Intangibles
- - - -
-
COGS Growth
+34.26% +57.76% +118.94% +175.68%
Gross Income
4.57M 43.44M 105.37M 281.00M
Gross Income Growth
+32.30% +850.34% +142.56% +166.68%
Gross Profit Margin
+45.27% +83.29% +84.66% +84.23%
2021 2022 2023 2024 5-year trend
SG&A Expense
158.92M 107.20M 168.65M 308.95M
Research & Development
89.70M 34.06M 34.24M 50.25M
Other SG&A
69.22M 73.14M 134.40M 258.69M
SGA Growth
+68.64% -32.54% +57.32% +83.19%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 325.00K
-
EBIT after Unusual Expense
(154.35M) (63.76M) (63.28M) (28.27M)
Non Operating Income/Expense
687.00K 1.63M 6.63M 9.50M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
4.50M 5.07M 8.87M 20.09M
Interest Expense Growth
-11.71% +12.68% +74.93% +126.44%
Gross Interest Expense
4.50M 5.07M 8.87M 20.09M
Interest Capitalized
- - - -
-
Pretax Income
(158.16M) (67.20M) (65.52M) (38.87M)
Pretax Income Growth
-67.70% +57.51% +2.50% +40.67%
Pretax Margin
-1,566.42% -128.84% -52.65% -11.65%
Income Tax
4.00K 8.00K 547.00K 266.00K
Income Tax - Current - Domestic
4.00K 8.00K 47.00K 266.00K
Income Tax - Current - Foreign
- - - 500.00K
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(158.16M) (67.21M) (66.07M) (39.14M)
Minority Interest Expense
- - - -
-
Net Income
(158.16M) (67.21M) (66.07M) (39.14M)
Net Income Growth
-67.70% +57.51% +1.70% +40.76%
Net Margin Growth
-1,566.46% -128.85% -53.08% -11.73%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(158.16M) (67.21M) (66.07M) (39.14M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(158.16M) (67.21M) (66.07M) (39.14M)
EPS (Basic)
-1.5178 -0.4235 -0.3012 -0.1664
EPS (Basic) Growth
-44.17% +72.10% +28.88% +44.75%
Basic Shares Outstanding
104.21M 158.69M 219.33M 235.23M
EPS (Diluted)
-1.5178 -0.4235 -0.3012 -0.1664
EPS (Diluted) Growth
-44.17% +72.10% +28.88% +44.75%
Diluted Shares Outstanding
104.21M 158.69M 219.33M 235.23M
EBITDA
(149.82M) (59.16M) (61.98M) (25.89M)
EBITDA Growth
-72.59% +60.51% -4.78% +58.24%
EBITDA Margin
-1,483.81% -113.42% -49.80% -7.76%

Snapshot

Average Recommendation BUY Average Target Price 11.60
Number of Ratings 11 Current Quarters Estimate -0.033
FY Report Date 03 / 2026 Current Year's Estimate 0.156
Last Quarter’s Earnings 0.02 Median PE on CY Estimate N/A
Year Ago Earnings -0.234 Next Fiscal Year Estimate 0.598
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 9 9 11 8
Mean Estimate -0.03 0.01 0.16 0.60
High Estimates 0.02 0.05 0.58 0.93
Low Estimate -0.10 -0.03 -0.06 0.25
Coefficient of Variance -118.25 281.79 111.93 37.50

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 10 10 11
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Ardelyx Inc - ARDX

Date Name Shares Transaction Value
May 20, 2025 David M. Mott Director 2,496,871 Open market or private purchase of non-derivative security Non-derivative transaction at $3.29 per share 8,214,705.59
Apr 9, 2025 Michael G. Raab President & CEO; Director 1,657,253 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $0.99 per share 1,640,680.47
Apr 9, 2025 Michael G. Raab President & CEO; Director 1,615,587 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.59 per share 7,415,544.33
Apr 9, 2025 Michael G. Raab President & CEO; Director 436,667 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 28, 2025 Justin A. Renz Chief Financial Officer 422,648 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Justin A. Renz Chief Financial Officer 205,019 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Elizabeth Grammer See Remarks 317,723 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Elizabeth Grammer See Remarks 205,019 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Michael G. Raab President & CEO; Director 855,326 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Laura A. Williams Chief Medical Officer 409,004 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Laura A. Williams Chief Medical Officer 157,700 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Michael Kelliher See Remarks 296,680 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Michael Kelliher See Remarks 205,019 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Eric Foster Chief Commercial Officer 316,680 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Eric Foster Chief Commercial Officer 205,019 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Ardelyx Inc in the News